Conclusion
AIED is one of the few forms of SNHL for which a treatment is available therefore early diagnosis and intervention is important. We report a case of secondary AIED in patient with a significant response to infliximab therapy. Studies on the use of anti-TNFα therapy for AIED as a steroid-sparing alternative are limited and showed variable results. To assess and establish the efficacy of anti-TNFα therapy in the management of AIED, large multicentre randomised controlled trials are required that measure not only improvement in hearing but also other aural symptoms. This, however, may be difficult due to the rarity of the condition and the lack of a standardised diagnostic criteria.